Online inquiry

IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2994MR)

This product GTTS-WQ2994MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2994MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7792MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ14342MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ2555MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ10894MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ4181MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ4912MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ2585MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ4121MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW